In the past week, FULC stock has gone down by -39.30%, with a monthly decline of -69.77% and a quarterly plunge of -35.15%. The volatility ratio for the week is 15.57%, and the volatility levels for the last 30 days are 10.83% for Fulcrum Therapeutics Inc. The simple moving average for the last 20 days is -52.69% for FULC stock, with a simple moving average of -50.15% for the last 200 days.
Is It Worth Investing in Fulcrum Therapeutics Inc. (NASDAQ: FULC) Right Now?
The 36-month beta value for FULC is also noteworthy at 2.28. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The average price estimated by analysts for FULC is $9.33, which is $5.53 above than the current price. The public float for FULC is 48.86M, and at present, short sellers hold a 8.29% of that float. The average trading volume of FULC on March 16, 2023 was 1.25M shares.
FULC) stock’s latest price update
Fulcrum Therapeutics Inc. (NASDAQ: FULC)’s stock price has decreased by -4.28 compared to its previous closing price of 3.97. However, the company has seen a fall of -39.30% in its stock price over the last five trading days.
Analysts’ Opinion of FULC
In the past week, FULC stock has gone down by -39.30%, with a monthly decline of -69.77% and a quarterly plunge of -35.15%. The volatility ratio for the week is 15.57%, and the volatility levels for the last 30 days are 10.83% for Fulcrum Therapeutics Inc. The simple moving average for the last 20 days is -52.69% for FULC stock, with a simple moving average of -50.15% for the last 200 days.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with H.C. Wainwright repeating the rating for FULC by listing it as a “Neutral.” The predicted price for FULC in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on March 10th of the current year 2023.
Credit Suisse, on the other hand, stated in their research note that they expect to see FULC reach a price target of $8, previously predicting the price at $11. The rating they have provided for FULC stocks is “Neutral” according to the report published on March 10th, 2023.
Stifel gave a rating of “Hold” to FULC, setting the target price at $6 in the report published on March 09th of the current year.
FULC Trading at -63.47% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.67% of loss for the given period.
Volatility was left at 10.83%, however, over the last 30 days, the volatility rate increased by 15.57%, as shares sank -70.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.80% lower at present.
During the last 5 trading sessions, FULC fell by -39.30%, which changed the moving average for the period of 200-days by -48.65% in comparison to the 20-day moving average, which settled at $7.58. In addition, Fulcrum Therapeutics Inc. saw -47.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from RA CAPITAL MANAGEMENT, L.P., who purchase 1,923,076 shares at the price of $13.00 back on Jan 20. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 11,609,704 shares of Fulcrum Therapeutics Inc., valued at $24,999,988 using the latest closing price.
Gould Robert J, the Interim President & CEO of Fulcrum Therapeutics Inc., sale 6,766 shares at $15.00 during a trade that took place back on Jan 13, which means that Gould Robert J is holding 499,864 shares at $101,490 based on the most recent closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -1768.12 for the present operating margin
- +61.94 for the gross margin
The net margin for Fulcrum Therapeutics Inc. stands at -1732.43.
The liquidity ratio also appears to be rather interesting for investors as it stands at 12.41.
Conclusion
In summary, Fulcrum Therapeutics Inc. (FULC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
